A biotechnology company developing targeted anti-infective antibodies to fight life-threatening infections - Elusys Therapeutics, Inc. (16140337) - has entered into an exclusive collaborative research and license agreement with Pfizer Inc. (NYSE: PFE) for the development of new therapeutics for select infectious diseases using Elusys' HP Antibody™ technology.
The said collaboration will include ETI-211, an HP Antibody for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, in addition to research into other indications.
T
he terms of agreement include the following:
- Elusys and Pfizer will collaborate on determining the full product profile of ETI-211 and perform research on other indications of the HP Antibody technology.
- Elusys will receive an upfront equity investment, research and development funding plus near-term research milestones.
- Elusys has also granted Pfizer an option to acquire an exclusive worldwide license to products developed under the agreement, and upon exercise, the company will receive significant clinical and sales milestones, as well as royalties on future sales of products resulting from the collaboration.
Find more details from the press release.
Comment Preview